Skip to main content
SpringerLink
Log in

Herztherapeutika

  • Chapter
Arzneiverordnungs-Report 2018

  • 2666 Accesses

Zusammenfassung

Herzglykoside gehen in ihren Verordnungszahlen unvermindert zurück, während sich Antiarrhythmika auf niedrigem Niveau stabilisiert haben. Für beide Gruppen fehlt eine klare Evidenz für prognostisch günstige Wirkungen, dazu haben Antiarrhythmika und Herzglykoside eine niedrige therapeutische Breite mit potentiell lebensbedrohlichen Nebenwirkungen. Die Verordnung von Nitraten und anderen Mitteln zur Behandlung der stabilen Angina pectoris wie Molsidomin, Ranolazin oder Ivabradin geht mit Ausnahme von Ranolazin ebenfalls zurück, was wahrscheinlich zum Teil einer Abnahme von Patienten mit stabiler Angina pectoris geschuldet ist. Mit der Kombination aus Sacubitril und Valsartan ist ein neues Therapieprinzip zur Behandlung der chronischen Herzinsuffizienz verfügbar, das 2017 trotz hoher Therapiekosten fast dreifach mehr verordnet wurde.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aarnoudse AL, Dieleman JP, Stricker BH (2007): Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30: 431–436

    Google Scholar 

  • Ahmed A, Waagstein F, Pitt B, White M, Zannad F, Young JB, Rahimtoola S (2009): Effectiveness of Digoxin in Reducing One-Year Mortality in Chronic Heart Failure in the Digitalis Investigation Group Trial. Am J Cardiol 103: 82–87

    Google Scholar 

  • Alexander KP, Weisz G, Prather K, James S, Mark DB et al. (2016): Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation 133: 39–47

    Google Scholar 

  • Arnold SV, Kosiborod M, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Spertus JA (2014): Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina. JAMA Intern Med 174: 1403–1405

    Google Scholar 

  • Barbato E, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B, Cardinal F, Vercauteren S, Wijns W (2015): Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: Results of the MEDCOR trial. Atherosclerosis 240: 351–354

    Google Scholar 

  • Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators (2005): Amiodaron or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352: 225–237

    Google Scholar 

  • Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2013): Nationale Versorgungsleitlinie Chronische Herzinsuffizienz. Kurzfassung 1. Auflage Version 7, Dezember 2009, zuletzt geändert: August 2013. AWMF-Reg.-Nr.: nvl/006

    Google Scholar 

  • Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L et al. PARADIGM-HF Investigators and Committees (2017): Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 19: 129–137

    Google Scholar 

  • Castagno D, Petrie MC, Claggett B, McMurray J (2012): Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 33: 1137–1141

    Google Scholar 

  • Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; PALLAS Investigators (2011): Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365: 2268–2276

    Google Scholar 

  • Deutsche Gesellschaft für Kardiologie – Herz-und Kreislaufforschung e.V. (2017): ESC Pocket Guidelines. Management von Vorhofflimmern, Version 2016. Börm Bruckmeier Verlag GmbH, Grünwald. Kurzfassung der „ESC Guidelines for the Management of Atrial Fibrillation“ European Heart Journal 2016; doi:10.1093/eurheartj/ehw210

  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. (1991): Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324: 781–788

    Google Scholar 

  • Fanaroff AC, James SK, Weisz G, Prather K, Anstrom KJ et al. (2017): Ranolazine after incomplete percutaneous coronary revascularization in patients with versus without diabetes mellitus: RIVER-PCI Trial. J Am Coll Cardiol 69: 2304–2313

    Google Scholar 

  • Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G (2004): Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 25: 1385–1394

    Google Scholar 

  • Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008): Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372: 807–816

    Google Scholar 

  • Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators (2014): Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371: 1091–1099

    Google Scholar 

  • Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M, Rostock T, Hsu LF, Sacher F, Reuter S, Clementy J, Haissaguerre M (2005): Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation 112: 3688–3696

    Google Scholar 

  • Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators (2009): Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360: 668–678

    Google Scholar 

  • Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ; PALLAS investigators (2014): Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol 7: 1019–1025

    Google Scholar 

  • Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, Steinbeck G, Treszl A, Wegscheider K, Breithardt G (2012): Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 380: 238–246

    Google Scholar 

  • Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, Amlie J, Carlsen J; Dronedarone Study Group (2008): Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358: 2678–2687

    Google Scholar 

  • Lehmann G, Reiniger G, Beyerle A, Schomig A (1998): Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine. J Cardiovasc Pharmacol 31: 25–30

    Google Scholar 

  • Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM (2010): A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol 21: 597–605

    Google Scholar 

  • Maresta A, Balducelli M, Latini R, Bernardi G, Moccetti T, Sosa C, Barlera S, Varani E, Ribeiro da Silva EE, Monici Preti A, Maggioni AP; STARC II Investigators (2005): Starc II, a multicenter randomized placebo-controlled doubleblind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. Catheter Cardiovasc Interv. 64: 375–382

    Google Scholar 

  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees (2014): Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993–1004

    Google Scholar 

  • Meinertz T, Lehmacher W for the Trapidil/ISDN Study Group (2006): Trapidil is as effective as isosorbidedinitrate for treating stable angina pectoris – a multinational, multicenter, double-blind, randomized study. Clin Res Cardiol. 95: 217–223

    Google Scholar 

  • Mest HJ (1990): Trapidil: a potent inhibitor of platelet aggregation. J Drug Dev 3: 143–149

    Google Scholar 

  • Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, Theroux P, Bode C, Braunwald E (2010): B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 55: 1189–1196

    Google Scholar 

  • Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML for the Multicenter Automatic Defibrillator Implantation Trial II Investigators (2002): Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346: 877–883

    Google Scholar 

  • Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, Muller HW, Meinertz T; SOPAT Investigators (2004): Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. Eur Heart J 25: 1395–1404

    Google Scholar 

  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG et al. (2016): 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. Mai 2016

    Google Scholar 

  • Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003): Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871–878

    Google Scholar 

  • Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators (2008): Rhythm control versus rat control for atrial fibrillation and heart failure. N Engl J Med 358: 2667–2677

    Google Scholar 

  • Sanders GD, Hlatky MA, Owens DK (2005): Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353: 1471–1480

    Google Scholar 

  • Schmiedl S, Szymanski J, Rottenkolber M, Hasford J, Thürmann PA (2007): Re: Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30: 1171–1173; author reply 1173–1174

    Google Scholar 

  • Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators (2010): Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376: 875–885

    Google Scholar 

  • The Digitalis Investigation Group (1997): The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533

    Google Scholar 

  • Tardif JC (2007): Clinical results of I(f) current inhibition by ivabradine. Drugs 67 Suppl 2: 35–41

    Google Scholar 

  • Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K (2005): Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26: 2529–2536

    Google Scholar 

  • Vamos M, Erath JW, Hohnloser SH (2015): Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 36: 1831–1838

    Google Scholar 

  • Vaughan Williams EM (1975): Classification of antidysrhythmic drugs. Pharmac Ther B 1: 115–138

    Google Scholar 

  • Wagner F, Gohlke-Barwolf C, Trenk D, Jähnchen E, Roskamm H (1991): Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris. Eur Heart J 12: 994–999

    Google Scholar 

  • Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M et al. (2016): Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, doubleblind, placebo-controlled trial. Lancet 387: 136–145

    Google Scholar 

  • Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002): A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: 1825–1833

    Google Scholar 

  • Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH, Steeds RP, Townend J, Kotecha D (2015): Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351: h4451

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    Thomas Eschenhagen

Authors
  1. Thomas Eschenhagen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Cite this chapter

Eschenhagen, T. (2018). Herztherapeutika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57386-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57386-0_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57385-3

  • Online ISBN: 978-3-662-57386-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation